Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Corp ADR LEGN
News
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
Legend Biotech Shares Rise After Swinging to 2Q Profit, Higher Revenue
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Legend Biotech Shares Fall After CEO Huang Resigns
Legend Biotech CEO Ying Huang Resigns
Legend Biotech Announces CEO Transition
Stocks to Watch: Smith & Wesson, Logistic Properties of the Americas, Legend Biotech
Legend Biotech ADSs Fall After Company Announces Public Offering
Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
Legend Biotech Down Over 14%, on Track for Record Low Close — Data Talk
United States